Clinical trials: Clopidogrel Resistance
Acute Coronary Syndrome
Efficacy and Safety Study of Ticagrelor
The purpose of this study is to compare the efficacy and safety of ticagrelor with clopidogrel
- Trial name
- NCT01812330
- Testing
- Clopidogrel, Ticagrelor
- Where
- China
- Volunteers
- 180 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Coronary Artery Disease, Clopidogrel Resistance
The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models
The study purposed to learn how clopidogrel-based antiplatelet treatment for preventing adverse cardiovascular events after ePCI works in chronic coronary artery disease when guided by personal genetic characteristics for drug…
- Conditions
- Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac Events
- Trial name
- NCT06665919
- Testing
- CYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
- Where
- 4 sites in Georgia
- Volunteers
- 283 people
- Sponsor
- Vistamedi Ltd.
Angioplasty, Transluminal, Percutaneous Coronary
Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance
This study will evaluate whether adding tirofiban, administered at high bolus dose on top of aspirin and clopidogrel will lead to a lower rate of periprocedural myocardial infarction after percutaneous coronary intervention in…
- Trial name
- 3T/2R (NCT00398463)
- Testing
- Tirofiban
- Where
- Italy
- Volunteers
- 263 people
- Sponsor
- Università degli Studi di Ferrara
Multi Vessel Coronary Artery Disease
Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass
Ticagrelor, a direct-acting oral P2Y12-receptor antagonist, provides greater and more consistent platelet inhibition than clopidogrel.
- Trial name
- NCT05166538
- Testing
- Ticagrelor, Clopidogrel
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Yonsei University
Coronary Heart Disease, Angina Pectoris
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.
In the ASCET study, 1000 patients with documented coronary heart disease will be randomized to either continued treatment with aspirin 160 mg/d or change to clopidogrel 75mg/d.
- Conditions
- Coronary Heart Disease, Angina Pectoris, Atherosclerosis
- Trial name
- ASCET (NCT00222261)
- Testing
- aspirin, clopidogrel
- Where
- Norway
- Volunteers
- 1,001 people
- Sponsor
- Ullevaal University Hospital
Ischemic Stroke, TIA (Transient Ischemic Attack)
Evaluation of the Efficacy of Novel Biomarkers in Predicting Clopidogrel Resistance in Patients with Ischemic Stroke
The goal of this observational study is to explore the potential efficacy of related biomakers in predicting clopidogrel resistance in patients with ischemic stroke. To be specific : 1.
- Conditions
- Ischemic Stroke, TIA (Transient Ischemic Attack), Clopidogrel Resistance
- Trial name
- NCT06753149
- Volunteers
- 800 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Peripheral Arterial Disease (PAD), Amputation
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore…
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- NCT07613840
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 484 people
- Sponsor
- Massachusetts General Hospital
Coronary Artery Disease, Drug Resistance
Effect of Clopidogrel Loading and Risk of PCI
This study is a prospective, single-center evaluation of the impact of the variability in platelet response after loading with clopidogrel on the peri-interventional risk of patients undergoing PCI.
- Trial name
- EXCELSIOR (NCT00457236)
- Where
- Germany
- Volunteers
- 800 people
- Sponsor
- University Heart Center Freiburg - Bad Krozingen
Cerebral Infarction, Clopidogrel,Poor Metabolism of (Disorder)
The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized and Cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction
The investigators team had found that the presence of dynamic changes of Clopidogrel resistance are not associated with genetic factors.
- Trial name
- NCT02411903
- Testing
- atorvastatin and clopidogrel, rosuvastatin and clopidogrel
- Volunteers
- 160 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Coronary Artery Disease
Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole
Clopidogrel, an inhibitor of ADP induced platelet aggregation and activation, is one of the most commonly used drugs in patients with cardiovascular disease.
- Trial name
- NCT01094275
- Testing
- Clopidogrel 75mg, Omeprazole 20mg
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Neil Kleiman, MD
Coronary Artery Disease, Acute Coronary Syndrome
Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention
This is a single-center, randomized, single-blind, investigator-initiated pharmacological study with a crossover design. Patients with acute coronary syndrome (ST-elevation myocardial infarction, non-ST elevation myocardial…
- Trial name
- NCT01360437
- Testing
- Prasugrel, Ticagrelor
- Where
- Greece
- Volunteers
- 44 people
- Sponsor
- University of Patras
Coronary Artery Disease
Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects
There is conflicting evidence in the literature suggesting that the use of proton pump inhibitors (PPIs), and/or some statins can interfere with clopidogrel antiplatelet effect and result in adverse cardiovascular outcomes in…
- Trial name
- SPICE (NCT00930670)
- Testing
- Rosuvastatin-omeprazole, Rosuvastatin-pantoprazole, Rosuvastatin-esomeprazole
- Where
- Canada
- Volunteers
- 320 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Peripheral Arterial Disease, Clopidogrel, Poor Metabolism of
Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease
This study evaluates the effects of Aspirin and thienopyridine resistance in relation to clinical cardiovascular outcomes as the genetic predictors of, and outcomes associated with aspirin and thienopyridine resistance in…
- Trial name
- NCT03174990
- Where
- United States
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Disease Susceptibility
Clopidogrel Pharmacogenomics Project
Loss-of-function mutation of the gene encoding the CYP450 2C19 enzyme has emerged as a likely determinant of resistance to clopidogrel therapy.
- Trial name
- NCT01097343
- Testing
- clopidogrel 75 mg, Clopidogrel 150 mg
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of North Carolina, Chapel Hill
Acute Ischemic Stroke, Clopidogrel Resistance
Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE
The objective of this clinical trial is to evaluate the efficacy and safety of platelet aggregation function - guided precision anti - platelet therapy in patients with acute cerebral infarction.
- Trial name
- PATH STROKE C (NCT06853535)
- Testing
- The ticagrelor, The Clopidogrel
- Where
- China
- Volunteers
- 5,138 people
- Sponsor
- Sichuan Provincial People's Hospital
Coronary Artery Disease, Drug Resistance
Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition
This study is a prospective, single-center evaluation of the efficacy of clopidogrel dose adjustment in patients with insufficient platelet inhibition after elective coronary stent implantation.
- Trial name
- NCT00302913
- Testing
- Adjustment of clopidogrel dose
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- University Heart Center Freiburg - Bad Krozingen
Coronary Artery Disease
The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance
Continuing high dose clopidogrel treatment after elective PCI decreased adverse cardiac events in patients with clopidogrel resistance
- Trial name
- EFFICIENT (NCT01032668)
- Testing
- Clopidogrel
- Where
- Turkey (Türkiye)
- Volunteers
- 192 people
- Sponsor
- Bursa Postgraduate Hospital
Drug Resistance
Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE)
A clopidogrel resistance rate of 40-50% has been found in the population over 70 years of age, whereas biological resistance, associated with an increased risk of cardiovascular events, is observed in about 20-30% of younger…
- Trial name
- CEPAGE (NCT04990596)
- Testing
- additional blood sample
- Where
- 4 sites in France
- Volunteers
- 37 people
- Sponsor
- Rennes University Hospital
Acute Myocardial Infarction
REsistance to Aspirin and Clopidogrel in acuTe Myocardial Infarction
The purpose of this study is to compare 3 point-of-care methods for monitoring antiplatelet therapy to golden standard (Light transmittance aggregometry-LTA) in high risk population of acute myocardial infarction patients.
- Trial name
- REACT-MI (NCT01381185)
- Testing
- Aspirin 200mg qd, Clopidogrel 2x75mg qd
- Where
- 2 sites in Czechia
- Volunteers
- 154 people
- Sponsor
- University Hospital Ostrava
Drug Resistance
Aspirin and Clopidogrel Resistance Study
Resistance to antiplatelet drugs (aspirin, clopidogrel) is a recognized phenomenon with a prevalence from 17% to 35%. Resistance as detected by in vitro tests such as Multiple Electrode Aggregometry (MEA) has been shown to…
- Trial name
- NCT01039480
- Where
- Switzerland
- Volunteers
- 82 people
- Sponsor
- University Hospital, Basel, Switzerland